The global RNAi for Therapeutic market size was valued at USD 181.1 million in 2022 and is forecast to a readjusted size of USD 2031.2 million by 2029 with a CAGR of 41.2% during review period.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%. US is the largest market, with a share over 75%, followed by EU, which has a share about 3%. In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
This report is a detailed and comprehensive analysis for global RNAi for Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global RNAi for Therapeutic market size and forecasts, in consumption value ($ Million), 2018-2029
Global RNAi for Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global RNAi for Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global RNAi for Therapeutic market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for RNAi for Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global RNAi for Therapeutic market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
siRNA
miRNA
shRNA
Cancer
Cardiovascular
HBV
Others
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe RNAi for Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNAi for Therapeutic, with revenue, gross margin and global market share of RNAi for Therapeutic from 2018 to 2023.
Chapter 3, the RNAi for Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and RNAi for Therapeutic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of RNAi for Therapeutic.
Chapter 13, to describe RNAi for Therapeutic research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of RNAi for Therapeutic
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RNAi for Therapeutic by Type
1.3.1 Overview: Global RNAi for Therapeutic Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global RNAi for Therapeutic Consumption Value Market Share by Type in 2022
1.3.3 siRNA
1.3.4 miRNA
1.3.5 shRNA
1.4 Global RNAi for Therapeutic Market by Application
1.4.1 Overview: Global RNAi for Therapeutic Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Cancer
1.4.3 Cardiovascular
1.4.4 HBV
1.4.5 Others
1.5 Global RNAi for Therapeutic Market Size & Forecast
1.6 Global RNAi for Therapeutic Market Size and Forecast by Region
1.6.1 Global RNAi for Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global RNAi for Therapeutic Market Size by Region, (2018-2029)
1.6.3 North America RNAi for Therapeutic Market Size and Prospect (2018-2029)
1.6.4 Europe RNAi for Therapeutic Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific RNAi for Therapeutic Market Size and Prospect (2018-2029)
1.6.6 South America RNAi for Therapeutic Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa RNAi for Therapeutic Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Alnylam Pharmaceuticals
2.1.1 Alnylam Pharmaceuticals Details
2.1.2 Alnylam Pharmaceuticals Major Business
2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
2.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.2 Arbutus Biopharma (Tekmira)
2.2.1 Arbutus Biopharma (Tekmira) Details
2.2.2 Arbutus Biopharma (Tekmira) Major Business
2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
2.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
2.3 Arrowhead
2.3.1 Arrowhead Details
2.3.2 Arrowhead Major Business
2.3.3 Arrowhead RNAi for Therapeutic Product and Solutions
2.3.4 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Arrowhead Recent Developments and Future Plans
2.4 Dicerna Pharmaceuticals
2.4.1 Dicerna Pharmaceuticals Details
2.4.2 Dicerna Pharmaceuticals Major Business
2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
2.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
2.5 Mirna Therapeutics
2.5.1 Mirna Therapeutics Details
2.5.2 Mirna Therapeutics Major Business
2.5.3 Mirna Therapeutics RNAi for Therapeutic Product and Solutions
2.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Mirna Therapeutics Recent Developments and Future Plans
2.6 Quark Pharmaceuticals
2.6.1 Quark Pharmaceuticals Details
2.6.2 Quark Pharmaceuticals Major Business
2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
2.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Quark Pharmaceuticals Recent Developments and Future Plans
2.7 RXi Pharmaceuticals
2.7.1 RXi Pharmaceuticals Details
2.7.2 RXi Pharmaceuticals Major Business
2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
2.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 RXi Pharmaceuticals Recent Developments and Future Plans
2.8 Silence Therapeutics
2.8.1 Silence Therapeutics Details
2.8.2 Silence Therapeutics Major Business
2.8.3 Silence Therapeutics RNAi for Therapeutic Product and Solutions
2.8.4 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Silence Therapeutics Recent Developments and Future Plans
2.9 Benitec Biopharma
2.9.1 Benitec Biopharma Details
2.9.2 Benitec Biopharma Major Business
2.9.3 Benitec Biopharma RNAi for Therapeutic Product and Solutions
2.9.4 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Benitec Biopharma Recent Developments and Future Plans
2.10 miRagen Therapeutics
2.10.1 miRagen Therapeutics Details
2.10.2 miRagen Therapeutics Major Business
2.10.3 miRagen Therapeutics RNAi for Therapeutic Product and Solutions
2.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 miRagen Therapeutics Recent Developments and Future Plans
2.11 Sylentis
2.11.1 Sylentis Details
2.11.2 Sylentis Major Business
2.11.3 Sylentis RNAi for Therapeutic Product and Solutions
2.11.4 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Sylentis Recent Developments and Future Plans
2.12 Gradalis
2.12.1 Gradalis Details
2.12.2 Gradalis Major Business
2.12.3 Gradalis RNAi for Therapeutic Product and Solutions
2.12.4 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Gradalis Recent Developments and Future Plans
2.13 Sirnaomics
2.13.1 Sirnaomics Details
2.13.2 Sirnaomics Major Business
2.13.3 Sirnaomics RNAi for Therapeutic Product and Solutions
2.13.4 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Sirnaomics Recent Developments and Future Plans
2.14 Silenseed
2.14.1 Silenseed Details
2.14.2 Silenseed Major Business
2.14.3 Silenseed RNAi for Therapeutic Product and Solutions
2.14.4 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Silenseed Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global RNAi for Therapeutic Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of RNAi for Therapeutic by Company Revenue
3.2.2 Top 3 RNAi for Therapeutic Players Market Share in 2022
3.2.3 Top 6 RNAi for Therapeutic Players Market Share in 2022
3.3 RNAi for Therapeutic Market: Overall Company Footprint Analysis
3.3.1 RNAi for Therapeutic Market: Region Footprint
3.3.2 RNAi for Therapeutic Market: Company Product Type Footprint
3.3.3 RNAi for Therapeutic Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global RNAi for Therapeutic Consumption Value and Market Share by Type (2018-2023)
4.2 Global RNAi for Therapeutic Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global RNAi for Therapeutic Consumption Value Market Share by Application (2018-2023)
5.2 Global RNAi for Therapeutic Market Forecast by Application (2024-2029)
6 North America
6.1 North America RNAi for Therapeutic Consumption Value by Type (2018-2029)
6.2 North America RNAi for Therapeutic Consumption Value by Application (2018-2029)
6.3 North America RNAi for Therapeutic Market Size by Country
6.3.1 North America RNAi for Therapeutic Consumption Value by Country (2018-2029)
6.3.2 United States RNAi for Therapeutic Market Size and Forecast (2018-2029)
6.3.3 Canada RNAi for Therapeutic Market Size and Forecast (2018-2029)
6.3.4 Mexico RNAi for Therapeutic Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe RNAi for Therapeutic Consumption Value by Type (2018-2029)
7.2 Europe RNAi for Therapeutic Consumption Value by Application (2018-2029)
7.3 Europe RNAi for Therapeutic Market Size by Country
7.3.1 Europe RNAi for Therapeutic Consumption Value by Country (2018-2029)
7.3.2 Germany RNAi for Therapeutic Market Size and Forecast (2018-2029)
7.3.3 France RNAi for Therapeutic Market Size and Forecast (2018-2029)
7.3.4 United Kingdom RNAi for Therapeutic Market Size and Forecast (2018-2029)
7.3.5 Russia RNAi for Therapeutic Market Size and Forecast (2018-2029)
7.3.6 Italy RNAi for Therapeutic Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2018-2029)
8.2 Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2018-2029)
8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region
8.3.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2018-2029)
8.3.2 China RNAi for Therapeutic Market Size and Forecast (2018-2029)
8.3.3 Japan RNAi for Therapeutic Market Size and Forecast (2018-2029)
8.3.4 South Korea RNAi for Therapeutic Market Size and Forecast (2018-2029)
8.3.5 India RNAi for Therapeutic Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia RNAi for Therapeutic Market Size and Forecast (2018-2029)
8.3.7 Australia RNAi for Therapeutic Market Size and Forecast (2018-2029)
9 South America
9.1 South America RNAi for Therapeutic Consumption Value by Type (2018-2029)
9.2 South America RNAi for Therapeutic Consumption Value by Application (2018-2029)
9.3 South America RNAi for Therapeutic Market Size by Country
9.3.1 South America RNAi for Therapeutic Consumption Value by Country (2018-2029)
9.3.2 Brazil RNAi for Therapeutic Market Size and Forecast (2018-2029)
9.3.3 Argentina RNAi for Therapeutic Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2018-2029)
10.2 Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2018-2029)
10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country
10.3.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2018-2029)
10.3.2 Turkey RNAi for Therapeutic Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia RNAi for Therapeutic Market Size and Forecast (2018-2029)
10.3.4 UAE RNAi for Therapeutic Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 RNAi for Therapeutic Market Drivers
11.2 RNAi for Therapeutic Market Restraints
11.3 RNAi for Therapeutic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 RNAi for Therapeutic Industry Chain
12.2 RNAi for Therapeutic Upstream Analysis
12.3 RNAi for Therapeutic Midstream Analysis
12.4 RNAi for Therapeutic Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global RNAi for Therapeutic Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global RNAi for Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global RNAi for Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Alnylam Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 6. Alnylam Pharmaceuticals Major Business
Table 7. Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
Table 8. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Alnylam Pharmaceuticals Recent Developments and Future Plans
Table 10. Arbutus Biopharma (Tekmira) Company Information, Head Office, and Major Competitors
Table 11. Arbutus Biopharma (Tekmira) Major Business
Table 12. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
Table 13. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
Table 15. Arrowhead Company Information, Head Office, and Major Competitors
Table 16. Arrowhead Major Business
Table 17. Arrowhead RNAi for Therapeutic Product and Solutions
Table 18. Arrowhead RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Arrowhead Recent Developments and Future Plans
Table 20. Dicerna Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 21. Dicerna Pharmaceuticals Major Business
Table 22. Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
Table 23. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Dicerna Pharmaceuticals Recent Developments and Future Plans
Table 25. Mirna Therapeutics Company Information, Head Office, and Major Competitors
Table 26. Mirna Therapeutics Major Business
Table 27. Mirna Therapeutics RNAi for Therapeutic Product and Solutions
Table 28. Mirna Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Mirna Therapeutics Recent Developments and Future Plans
Table 30. Quark Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 31. Quark Pharmaceuticals Major Business
Table 32. Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
Table 33. Quark Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Quark Pharmaceuticals Recent Developments and Future Plans
Table 35. RXi Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 36. RXi Pharmaceuticals Major Business
Table 37. RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
Table 38. RXi Pharmaceuticals RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. RXi Pharmaceuticals Recent Developments and Future Plans
Table 40. Silence Therapeutics Company Information, Head Office, and Major Competitors
Table 41. Silence Therapeutics Major Business
Table 42. Silence Therapeutics RNAi for Therapeutic Product and Solutions
Table 43. Silence Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Silence Therapeutics Recent Developments and Future Plans
Table 45. Benitec Biopharma Company Information, Head Office, and Major Competitors
Table 46. Benitec Biopharma Major Business
Table 47. Benitec Biopharma RNAi for Therapeutic Product and Solutions
Table 48. Benitec Biopharma RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Benitec Biopharma Recent Developments and Future Plans
Table 50. miRagen Therapeutics Company Information, Head Office, and Major Competitors
Table 51. miRagen Therapeutics Major Business
Table 52. miRagen Therapeutics RNAi for Therapeutic Product and Solutions
Table 53. miRagen Therapeutics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. miRagen Therapeutics Recent Developments and Future Plans
Table 55. Sylentis Company Information, Head Office, and Major Competitors
Table 56. Sylentis Major Business
Table 57. Sylentis RNAi for Therapeutic Product and Solutions
Table 58. Sylentis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Sylentis Recent Developments and Future Plans
Table 60. Gradalis Company Information, Head Office, and Major Competitors
Table 61. Gradalis Major Business
Table 62. Gradalis RNAi for Therapeutic Product and Solutions
Table 63. Gradalis RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Gradalis Recent Developments and Future Plans
Table 65. Sirnaomics Company Information, Head Office, and Major Competitors
Table 66. Sirnaomics Major Business
Table 67. Sirnaomics RNAi for Therapeutic Product and Solutions
Table 68. Sirnaomics RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Sirnaomics Recent Developments and Future Plans
Table 70. Silenseed Company Information, Head Office, and Major Competitors
Table 71. Silenseed Major Business
Table 72. Silenseed RNAi for Therapeutic Product and Solutions
Table 73. Silenseed RNAi for Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Silenseed Recent Developments and Future Plans
Table 75. Global RNAi for Therapeutic Revenue (USD Million) by Players (2018-2023)
Table 76. Global RNAi for Therapeutic Revenue Share by Players (2018-2023)
Table 77. Breakdown of RNAi for Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3)
Table 78. Market Position of Players in RNAi for Therapeutic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 79. Head Office of Key RNAi for Therapeutic Players
Table 80. RNAi for Therapeutic Market: Company Product Type Footprint
Table 81. RNAi for Therapeutic Market: Company Product Application Footprint
Table 82. RNAi for Therapeutic New Market Entrants and Barriers to Market Entry
Table 83. RNAi for Therapeutic Mergers, Acquisition, Agreements, and Collaborations
Table 84. Global RNAi for Therapeutic Consumption Value (USD Million) by Type (2018-2023)
Table 85. Global RNAi for Therapeutic Consumption Value Share by Type (2018-2023)
Table 86. Global RNAi for Therapeutic Consumption Value Forecast by Type (2024-2029)
Table 87. Global RNAi for Therapeutic Consumption Value by Application (2018-2023)
Table 88. Global RNAi for Therapeutic Consumption Value Forecast by Application (2024-2029)
Table 89. North America RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 90. North America RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 91. North America RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 92. North America RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 93. North America RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 94. North America RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 95. Europe RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Europe RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Europe RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 98. Europe RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 99. Europe RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 100. Europe RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 101. Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 102. Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 103. Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 104. Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 105. Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
Table 106. Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
Table 107. South America RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 108. South America RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 109. South America RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 110. South America RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 111. South America RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 112. South America RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 114. Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 115. Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 116. Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 117. Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 118. Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 119. RNAi for Therapeutic Raw Material
Table 120. Key Suppliers of RNAi for Therapeutic Raw Materials
List of Figures
Figure 1. RNAi for Therapeutic Picture
Figure 2. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global RNAi for Therapeutic Consumption Value Market Share by Type in 2022
Figure 4. siRNA
Figure 5. miRNA
Figure 6. shRNA
Figure 7. Global RNAi for Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. RNAi for Therapeutic Consumption Value Market Share by Application in 2022
Figure 9. Cancer Picture
Figure 10. Cardiovascular Picture
Figure 11. HBV Picture
Figure 12. Others Picture
Figure 13. Global RNAi for Therapeutic Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global RNAi for Therapeutic Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market RNAi for Therapeutic Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global RNAi for Therapeutic Consumption Value Market Share by Region (2018-2029)
Figure 17. Global RNAi for Therapeutic Consumption Value Market Share by Region in 2022
Figure 18. North America RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 21. South America RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 23. Global RNAi for Therapeutic Revenue Share by Players in 2022
Figure 24. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players RNAi for Therapeutic Market Share in 2022
Figure 26. Global Top 6 Players RNAi for Therapeutic Market Share in 2022
Figure 27. Global RNAi for Therapeutic Consumption Value Share by Type (2018-2023)
Figure 28. Global RNAi for Therapeutic Market Share Forecast by Type (2024-2029)
Figure 29. Global RNAi for Therapeutic Consumption Value Share by Application (2018-2023)
Figure 30. Global RNAi for Therapeutic Market Share Forecast by Application (2024-2029)
Figure 31. North America RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 32. North America RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 33. North America RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 34. United States RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 41. France RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific RNAi for Therapeutic Consumption Value Market Share by Region (2018-2029)
Figure 48. China RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 51. India RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 54. South America RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 55. South America RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 56. South America RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa RNAi for Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa RNAi for Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa RNAi for Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE RNAi for Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 65. RNAi for Therapeutic Market Drivers
Figure 66. RNAi for Therapeutic Market Restraints
Figure 67. RNAi for Therapeutic Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of RNAi for Therapeutic in 2022
Figure 70. Manufacturing Process Analysis of RNAi for Therapeutic
Figure 71. RNAi for Therapeutic Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
